• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Smart Healthcare Is Taking Over. Here's Where the Money's Headed

    6/10/25 11:13:00 AM ET
    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    Catalog/Specialty Distribution
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology
    Get the next $AMZN alert in real time by email

    Issued on behalf of Avant Technologies Inc.

    Equity Insider News Commentary

    VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI tools. But as implementations increase across the sector, so too are major developments coming from innovators, including Avant Technologies, Inc. (OTCQB:AVAI), Renovaro Inc. (NASDAQ:RENB), Alphabet, Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL), Omada Health, Inc. (NASDAQ:OMDA), and Amazon.com, Inc. (NASDAQ:AMZN).

    Equity Insider Logo (PRNewsfoto/Equity Insider)

    McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030.

    Avant Technologies, Inc. (OTCQB:AVAI) has just taken a major step forward in its evolution from AI incubator to full-stack healthcare innovator. Today, the company announced it had signed a non-binding letter of intent to acquire 100% of Ainnova Tech, its joint venture partner and the developer of the Vision AI diagnostic platform. Prior to the acquisition, the two companies have been operating jointly through Ai-nova Acquisition Corp (AAC), which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments.

    "We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of AAC. "We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare."

    Under the proposed agreement, Ainnova would roll all of its outstanding equity into the combined public entity — unifying leadership and eliminating structural complexity ahead of a scheduled FDA pre-submission meeting in July.

    While final terms of the deal are still being negotiated, both companies say the merger would streamline commercialization and accelerate the rollout of Ainnova's flagship Vision AI technology — a platform already in use across clinical sites in Latin America for the early detection of diabetic retinopathy, cardiovascular disease, and other chronic conditions. The move also signals growing confidence from Avant's leadership as they prepare to bring proprietary hardware into the mix.

    In parallel with the merger discussions, Avant and Ainnova are entering the final prototyping stage of a low-cost, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics.

    The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel.

    The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics.

    "The cost of a fundus camera has always been a barrier to entry in this market," said Vargas. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market."

    Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare.

    "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions."

    As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care.

    CONTINUED... Read this and more news for Avant Technologies at:

    https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

    Renovaro Inc. (NASDAQ:RENB) recently announced a major expansion to its intellectual property portfolio with a newly approved U.S. patent for its AI-powered drug discovery and diagnostics infrastructure.

    "This patent is a strategic milestone for Renovaro," said David Weinstein, CEO of Renovaro. "Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights."

    The patent protects methods that harmonize genomic, imaging, clinical, and health record data into a standardized framework for large-scale predictive analytics. These capabilities are built for distributed computing environments, aligning with the biopharma industry's move toward real-time, scalable analytics. The development enhances Renovaro's competitive positioning in data-driven therapeutics and clinical insight markets.

    Alphabet, Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL) recently showcased its leadership in AI-driven cancer research at the 2025 ASCO Annual Meeting, where Ruth Porat discussed Alphabet's evolving role in early diagnosis and treatment.

    "AI has greater potential than the internet, because it can augment human capabilities," wrote Ruth Porat, President & Chief Investment Officer of Alphabet and Google, quoting Vint Cerf. "It is a partner for all of you, for each of us."

    Porat highlighted Google's success with AlphaFold, which has accelerated cancer drug discovery by solving the decades-long problem of protein folding. She also noted the company's AI-assisted pathology tools that cut diagnostic time in half and improve detection of small metastases. From scalable diabetic retinopathy screening to generative AI for clinical workflows, she framed AI as a transformative force in healthcare delivery.

    Omada Health, Inc. (NASDAQ:OMDA) entered the public markets with a strong debut, raising $150 million and closing its first trading day 21% above IPO pricing. The company delivers AI-augmented virtual care for chronic conditions like diabetes, hypertension, and obesity, serving more than 679,000 active members.

    In May, prior to the IPO, Omada introduced Nutritional Intelligence, a new member experience powered by OmadaSpark—an AI agent that offers personalized, evidence-based nutrition coaching between clinical visits. As demand rises for GLP-1 medications, Omada is positioning its human-plus-AI model as essential to long-term metabolic health.

    "We believe there is a clear market need for real-time educational support backed by behavioral science to improve mindsets and behaviors toward food," said Wei-Li Shao, President at Omada Health. "To meet the needs of our customers and members, Omada fine tuned its approach to offer AI-powered tools trained with clinical input and expertise to work alongside human care teams in helping members drive improved health and economic outcomes."

    Amazon.com, Inc. (NASDAQ:AMZN) continues to scale its digital health footprint via Amazon Web Services (AWS), which recently brought its HealthLake platform to the EU's Dublin Region. The move enables hospitals and insurers to unify siloed patient data using FHIR standards, while running AI-driven analytics and maintaining full data residency compliance.

    "I'm excited about AWS HealthLake launch in EU Region," said Ramon Postulart, CTO at Adapcare. "AWS HealthLake is a key AWS healthcare service helping us modernize interoperability across the 70+ care organizations and 60,000 health professionals we support in the Netherlands. By moving to this service, we're unlocking richer, standardized health data and leveraging the HealthLake fully managed capabilities to build smarter, AI-powered tools for care planning and coordination."

    HealthLake now serves as the engine behind personalized care tools in development across Ireland, the Netherlands, and Finland. AWS also hosted its Health Data & AI Day in Dublin to promote cross-border health data innovation and the European Health Data Space initiative.

    Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/  

    CONTACT:

    Equity Insider

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Logo - https://mma.prnewswire.com/media/2644233/5362794/Equity_Insider_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/smart-healthcare-is-taking-over-heres-where-the-moneys-headed-302477870.html

    SOURCE Equity Insider

    Get the next $AMZN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMZN
    $GOOG
    $GOOGL
    $OMDA

    CompanyDatePrice TargetRatingAnalyst
    Alphabet Inc.
    $GOOG
    7/24/2025$225.00 → $245.00Buy
    Pivotal Research Group
    Alphabet Inc.
    $GOOGL
    7/24/2025$210.00 → $220.00Buy
    Needham
    Amazon.com Inc.
    $AMZN
    7/23/2025$248.00 → $265.00Buy
    BofA Securities
    Amazon.com Inc.
    $AMZN
    7/22/2025$220.00 → $265.00Buy
    Needham
    Amazon.com Inc.
    $AMZN
    7/21/2025$220.00 → $244.00Outperform
    Robert W. Baird
    Alphabet Inc.
    $GOOGL
    7/15/2025$200.00 → $208.00Outperform
    BMO Capital Markets
    Amazon.com Inc.
    $AMZN
    7/11/2025$240.00 → $255.00Overweight
    Analyst
    Amazon.com Inc.
    $AMZN
    7/10/2025Mkt Outperform
    Citizens JMP
    More analyst ratings

    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Alphabet Inc.

      10-Q - Alphabet Inc. (0001652044) (Filer)

      7/23/25 7:44:01 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology
    • Alphabet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Alphabet Inc. (0001652044) (Filer)

      7/23/25 4:01:33 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 144 filed by Alphabet Inc.

      144 - Alphabet Inc. (0001652044) (Subject)

      7/18/25 4:47:18 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology

    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 11, 2025 - FDA Roundup: March 11, 2025

      For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

      3/13/25 3:14:00 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • November 14, 2023 - FDA Roundup: November 14, 2023

      For Immediate Release: November 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there

      11/14/23 3:26:18 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pivotal Research Group reiterated coverage on Alphabet with a new price target

      Pivotal Research Group reiterated coverage of Alphabet with a rating of Buy and set a new price target of $245.00 from $225.00 previously

      7/24/25 7:17:55 AM ET
      $GOOG
      Computer Software: Programming Data Processing
      Technology
    • Needham reiterated coverage on Alphabet A with a new price target

      Needham reiterated coverage of Alphabet A with a rating of Buy and set a new price target of $220.00 from $210.00 previously

      7/24/25 7:14:25 AM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology
    • BofA Securities reiterated coverage on Amazon with a new price target

      BofA Securities reiterated coverage of Amazon with a rating of Buy and set a new price target of $265.00 from $248.00 previously

      7/23/25 11:29:18 AM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Roundhill Investments Launches Five Additional WeeklyPay™ ETFs

      Roundhill WeeklyPay™ ETFs are designed to deliver weekly distributions while targeting enhanced weekly returns linked to investors' favorite stocks. NEW YORK, July 24, 2025 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of five new WeeklyPay™ ETFs, which begin trading on Cboe BZX today. Today's launch expands the Roundhill WeeklyPay™ ETF suite to fifteen funds, encompassing fifteen underlying stocks: AAPL, AMD, AMZN, AVGO, BRK/B, COIN, GOOGL, HOOD, META, MSFT, MSTR, NFLX, NVDA, PLTR, and TSLA. T

      7/24/25 9:00:00 AM ET
      $AAPL
      $AMD
      $AMZN
      $AVGO
      Computer Manufacturing
      Technology
      Semiconductors
      Catalog/Specialty Distribution
    • Roundhill WeeklyPay™ ETF Suite Surpasses $250 Million in AUM

      WeeklyPay™ ETFs are designed to deliver weekly income and uncapped upside on your favorite stocks. NEW YORK, July 23, 2025 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is excited to announce that its WeeklyPay™ ETF suite has exceeded $250 million in assets under management (AUM).¹ Roundhill WeeklyPay™ ETFs are designed to provide investors with weekly distributions while allowing investors to maintain uncapped upside exposure to their favorite stocks, unlike covered call funds. About Roundhill Investments: Founded in 2018, Roundhill Investments is an SEC-registered investment advisor focused on innovative exchange-traded funds. Roundhill's

      7/23/25 4:36:00 PM ET
      $AMZN
      $NVDA
      Catalog/Specialty Distribution
      Consumer Discretionary
      Semiconductors
      Technology
    • Buy with Prime Powers Revlon's Limited-Edition "Flavortown" Lip Balm Launch with Guy Fieri

      Customers can order Revlon's limited-edition Super Lustrous Glass Shine Lip Balm with the power of Amazon's fulfillment network and the trust of Prime Through fast, free delivery, easy returns, and 24/7 support, Buy with Prime enhances the purchasing experience for Revlon's limited lip balm drop Prime members get the familiar shopping benefits they know and love on Revlon.com Amazon (NASDAQ:AMZN) today announced that Revlon's limited-edition "Flavortown" shade of its Super Lustrous Glass Shine Lip Balm—created in collaboration with Guy Fieri—is exclusively available through Buy with Prime, a direct-to-customer (DTC) offering, now through July 29. Timed to celebrate National Lipstick D

      7/23/25 9:00:00 AM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chair Bezos Jeffrey P sold $1,509,959,637 worth of shares (6,612,707 units at $228.34), decreasing direct ownership by 0.74% to 887,933,999 units (SEC Form 4)

      4 - AMAZON COM INC (0001018724) (Issuer)

      7/23/25 4:30:09 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Shriram Kavitark Ram sold $6,235,220 worth of shares (33,566 units at $185.76), decreasing direct ownership by 7% to 243,400 units (SEC Form 4)

      4 - Alphabet Inc. (0001652044) (Issuer)

      7/21/25 4:47:16 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology
    • Chief Executive Officer Pichai Sundar sold $5,992,318 worth of Class C Capital Stock (32,500 units at $184.38), decreasing direct ownership by 1% to 2,527,392 units (SEC Form 4)

      4 - Alphabet Inc. (0001652044) (Issuer)

      7/17/25 6:06:42 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology

    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

      SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in

      6/17/25 9:00:00 AM ET
      $OMDA
      Medical/Nursing Services
      Health Care
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin

      2/26/25 1:25:00 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

      SC 13G/A - AMAZON COM INC (0001018724) (Subject)

      11/8/24 4:33:15 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

      SC 13G/A - AMAZON COM INC (0001018724) (Filed by)

      11/7/24 5:23:12 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      11/6/24 5:45:52 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMZN
    $GOOG
    $GOOGL
    $OMDA
    Financials

    Live finance-specific insights

    See more
    • Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

      SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

      7/17/25 4:30:00 PM ET
      $OMDA
      Medical/Nursing Services
      Health Care
    • Amazon.com to Webcast Second Quarter 2025 Financial Results Conference Call

      Amazon.com, Inc. (NASDAQ:AMZN) announced today that it will hold a conference call to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 2:00 p.m. PT/5:00 p.m. ET. The event will be webcast live, and the audio and associated slides will be available for at least three months thereafter at www.amazon.com/ir. View source version on businesswire.com: https://www.businesswire.com/news/home/20250717192665/en/ Amazon.com Public Relations [email protected] amazon.com/ir

      7/17/25 4:01:00 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Circus SE Successfully Acquires Agentic AI Company FullyAI

      FullyAI becomes the core AI intelligence layer powering operational guidance, prediction models, and personalized AI experiences across Circus' robotics and software stack Technology to leverage billions of data points from Circus robotic systems to scale a global intelligence network for its autonomous food systems and nutrition patterns FullyAI's team becomes part of Circus, including new leadership in AI and growth to scale the next phase of intelligent food autonomy Circus SE (XETRA: CA1), a global technology leader in AI-robotics for the food service industry, today announces the successful acquisition of agentic AI company FullyAI, marking a major milestone in its mission to bu

      5/21/25 4:18:00 AM ET
      $GOOGL
      $MCD
      $META
      $TSLA
      Computer Software: Programming Data Processing
      Technology
      Restaurants
      Consumer Discretionary